Cargando…

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

PURPOSE: Hypermethylation of promoter CpG islands (CIMP) has been strongly implicated in chemotherapy resistance and is implicated in the pathogenesis of a subset of colorectal cancers (CRCs) termed CIMP-high. EXPERIMENTAL DESIGN: This phase I/II study in CRC (phase II portion restricted to CIMP-hig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Overman, Michael J., Morris, Van, Moinova, Helen, Manyam, Ganiraju, Ensor, Joe, Lee, Michael S., Eng, Cathy, Kee, Bryan, Fogelman, David, Shroff, Rachna T., LaFramboise, Thomas, Mazard, Thibault, Feng, Tian, Hamilton, Stanley, Broom, Bradley, Lutterbaugh, James, Issa, Jean-Pierre, Markowitz, Sanford D., Kopetz, Scott
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341892/ https://www.ncbi.nlm.nih.gov/pubmed/27542211 http://dx.doi.org/10.18632/oncotarget.11317

Ejemplares similares

The DNMT1-associated lincRNA DACOR1 reprograms genome-wide DNA methylation in colon cancer
por: Somasundaram, Saigopal, et al.
Publicado: (2018)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment
por: Snoeren, Nikol, et al.
Publicado: (2010)

Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II)
por: Hattori, Norifumi, et al.
Publicado: (2019)

A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report
por: Uji, Masahito, et al.
Publicado: (2016)

Distinct epigenetic signatures elucidate enhancer-gene relationships that delineate CIMP and non-CIMP colorectal cancers
por: Chong, Allen, et al.
Publicado: (2016)

18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high
por: Ogino, Shuji, et al.
Publicado: (2007)

Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system
por: Bae, Jeong Mo, et al.
Publicado: (2017)

Expression and regulatory roles of lncRNAs in G-CIMP-low vs G-CIMP-high Glioma: an in-silico analysis
por: Datta, Indrani, et al.
Publicado: (2021)

Comparison of adjuvant capecitabine plus oxaliplatin (CAPOX) versus S-1 after gastrectomy: a population-based cohort study using a nationwide claims database
por: Maeng, Chi Hoon, et al.
Publicado: (2023)

Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system’
por: Tapial, Sandra, et al.
Publicado: (2018)

iBAG: integrative Bayesian analysis of high-dimensional multiplatform genomics data
por: Wang, Wenting, et al.
Publicado: (2013)

Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
por: Osawa, Hiroshi, et al.
Publicado: (2015)

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
por: Raghav, Kanwal, et al.
Publicado: (2016)

Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances
por: LaFramboise, Thomas
Publicado: (2009)

Reply to ‘Comment on ‘Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system”
por: Bae, Jeong Mo, et al.
Publicado: (2018)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Influence of DPYD*9A, DPYD*6 and GSTP1 ile105val Genetic Polymorphisms on Capecitabine and Oxaliplatin (CAPOX) Associated Toxicities in Colorectal Cancer (CRC) Patients
por: K, Ashok Varma, et al.
Publicado: (2019)

Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas
por: Li, Jie, et al.
Publicado: (2014)

The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation
por: Miller, Brendan F., et al.
Publicado: (2016)

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer
por: Lee, Michael S, et al.
Publicado: (2016)

The CpG island methylator phenotype (CIMP) in colorectal cancer
por: Mojarad, Ehsan Nazemalhosseini, et al.
Publicado: (2013)

CytoConverter: a web-based tool to convert karyotypes to genomic coordinates
por: Wang, Janet, et al.
Publicado: (2019)

Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts
por: Kanikarla Marie, Preeti, et al.
Publicado: (2022)

KPP: KEGG Pathway Painter
por: Manyam, Ganiraju, et al.
Publicado: (2015)

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer
por: Sarshekeh, Amir Mehrvarz, et al.
Publicado: (2017)

cIMP: Synthesis, effector activation, inactivation and occurrence in biological systems
por: Seifert, Roland, et al.
Publicado: (2015)

Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas
por: Yin, An-An, et al.
Publicado: (2019)

The CIMP-high phenotype is associated with energy metabolism alterations in colon adenocarcinoma
por: Fedorova, Maria S., et al.
Publicado: (2019)

Development and validation of a CIMP-associated prognostic model for hepatocellular carcinoma
por: Li, Ganxun, et al.
Publicado: (2019)

CIMP-positive glioma is associated with better prognosis: A systematic analysis
por: Xu, Yingying, et al.
Publicado: (2022)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction
por: Chouhan, Jay, et al.
Publicado: (2015)

Survival differences of CIMP subtypes integrated with CNA information in human breast cancer
por: Wang, Huihan, et al.
Publicado: (2017)

Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability
por: Flatin, Bjørnar T.B., et al.
Publicado: (2020)

An efficient algorithm for systematic analysis of nucleotide strings suitable for siRNA design
por: Baranova, Ancha, et al.
Publicado: (2011)

Integrative Analysis of mRNA, microRNA, and Protein Correlates of Relative Cerebral Blood Volume Values in GBM Reveals the Role for Modulators of Angiogenesis and Tumor Proliferation
por: Rao, Arvind, et al.
Publicado: (2016)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

G-Cimp Status Prediction Of Glioblastoma Samples Using mRNA Expression Data
por: Baysan, Mehmet, et al.
Publicado: (2012)

Hypoxic Vasospasm Mediated by cIMP: When Soluble Guanylyl Cyclase Turns Bad
por: Gao, Yuansheng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6tvpnpdvsfp5fjmonjoofbd78u